These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 33822400)
1. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo. Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400 [TBL] [Abstract][Full Text] [Related]
2. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. Han D; Yu T; Dong N; Wang B; Sun F; Jiang D J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685 [TBL] [Abstract][Full Text] [Related]
3. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells. Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847 [TBL] [Abstract][Full Text] [Related]
4. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells. Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779 [TBL] [Abstract][Full Text] [Related]
6. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Hubbard JM; Grothey A Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435 [TBL] [Abstract][Full Text] [Related]
7. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma. Li X; Wei Y; Wei X Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587 [TBL] [Abstract][Full Text] [Related]
8. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236 [TBL] [Abstract][Full Text] [Related]
9. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3). Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602 [TBL] [Abstract][Full Text] [Related]
10. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells. Löcken H; Clamor C; Müller K J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365 [TBL] [Abstract][Full Text] [Related]
12. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone. Shao Z; Wang H; Ren H; Sun Y; Chen X Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646 [TBL] [Abstract][Full Text] [Related]
13. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death. Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169 [TBL] [Abstract][Full Text] [Related]
14. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Hagberg Thulin M; Jennbacken K; Damber JE; Welén K Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404 [TBL] [Abstract][Full Text] [Related]
15. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines. Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097 [TBL] [Abstract][Full Text] [Related]
16. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873 [TBL] [Abstract][Full Text] [Related]
17. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Guha P; Gardell J; Darpolor J; Cunetta M; Lima M; Miller G; Espat NJ; Junghans RP; Katz SC Oncogene; 2019 Jan; 38(4):533-548. PubMed ID: 30158673 [TBL] [Abstract][Full Text] [Related]
18. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers. Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Shukeir N; Stefanska B; Parashar S; Chik F; Arakelian A; Szyf M; Rabbani SA Br J Pharmacol; 2015 Jun; 172(11):2769-81. PubMed ID: 25631332 [TBL] [Abstract][Full Text] [Related]
20. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism. Leijten NM; Bakker P; Spaink HP; den Hertog J; Lemeer S Mol Cell Proteomics; 2021; 20():100033. PubMed ID: 33594990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]